
Various Mechanisms May Inform Nivolumab Use in Gastroesophageal Cancer
The decision to treat patients with nivolumab (Opdivo)-based therapies vs chemotherapy alone in patients with gastroesophageal cancer may be informed by anti–PD-1 and anti–CTLA-4 mechanisms, according to results from an exploratory analysis of the phase 3 …